Suscribirse

Atopic dermatitis phenotype affects expression of atopic diseases despite similar mononuclear cell cytokine response - 05/06/24

Doi : 10.1016/j.jaci.2024.02.015 
Mohamed H. Taki, MD a, b, Kristine E. Lee, MS c, Ronald Gangnon, PhD c, James E. Gern, MD a, b, Robert F. Lemanske, MD a, b, Daniel J. Jackson, MD a, , Anne Marie Singh, MD a,
a Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wis 
b Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis 
c Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wis 

Corresponding authors: Anne Marie Singh, MD, or Daniel J. Jackson, MD, 600 Highland Ave, K4/916, Madison, WI 53792.600 Highland AveK4/916MadisonWI53792

Abstract

Background

The atopic march refers to the coexpression and progression of atopic diseases in childhood, often beginning with atopic dermatitis (AD), although children may not progress through each atopic disease.

Objective

We hypothesized that future atopic disease expression is modified by AD phenotype and that these differences result from underlying dysregulation of cytokine signaling.

Methods

Children (n = 285) were enrolled into the Childhood Origins of Asthma (COAST) birth cohort and followed prospectively. Rates of AD, food allergy, allergic rhinitis, and asthma were assessed longitudinally from birth to 18 years of age. Associations between AD phenotype and food allergy, allergic rhinitis, asthma, allergic sensitization, exhaled nitric oxide, and lung function were determined. Peripheral blood mononuclear cell responses (IL-5, IL-10, IL-13, IFN-γ) to dust mite, phytohemagglutinin, Staphylococcus aureus Cowan I, and tetanus toxoid were compared among AD phenotypes.

Results

AD at year 1 was associated with an increased risk of food allergy (P = .004). Both persistent and late-onset AD were associated with an increased risk of asthma (P < .001), rhinitis (P < .001), elevated total IgE (P < .001), percentage of aeroallergens with detectable IgE (P < .001), and elevated exhaled nitric oxide (P = .002). Longitudinal analyses did not reveal consistent differences in peripheral blood mononuclear cell responses among dermatitis phenotypes.

Conclusion

AD phenotype is associated with differential expression of other atopic diseases. Our findings suggest that peripheral blood cytokine dysregulation is not a mechanism underlying this process, and immune dysregulation may be mediated at mucosal surfaces or in secondary lymphoid organs.

El texto completo de este artículo está disponible en PDF.

Key words : Atopic dermatitis, atopic march, atopic dermatitis phenotypes, allergic sensitization, progression of atopic disease

Abbreviations used : AD, CCL, COAST, Feno, FEV1, FVC, PBMC, TSLP


Esquema


 The last 2 authors contributed equally to this article, and both should be considered senior author.


© 2024  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 153 - N° 6

P. 1604 - juin 2024 Regresar al número
Artículo precedente Artículo precedente
  • Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants
  • Georgios N. Stamatas, Takahiro Sato, Carol Ní Chaoimh, Thierry Oddos, Richard Insel, Jonathan O’B. Hourihane, Alan D. Irvine
| Artículo siguiente Artículo siguiente
  • Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy
  • Tarun Keswani, Nicole A. LaHood, Orlee Marini-Rapoport, Bijoya Karmakar, Léna Andrieux, Brian Reese, Sunny L. Sneed, Lars C. Pedersen, Geoffrey A. Mueller, Sarita U. Patil

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.